1. Home
  2. TVTX vs NAMS Comparison

TVTX vs NAMS Comparison

Compare TVTX & NAMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • TVTX
    SELLHOLDBUYas of 2 days ago
  • NAMS
    SELLHOLDBUYas of 2 days ago
  • Stock Information
  • Founded
  • TVTX 2008
  • NAMS 2019
  • Country
  • TVTX United States
  • NAMS Netherlands
  • Employees
  • TVTX N/A
  • NAMS N/A
  • Industry
  • TVTX Biotechnology: Pharmaceutical Preparations
  • NAMS Biotechnology: Pharmaceutical Preparations
  • Sector
  • TVTX Health Care
  • NAMS Health Care
  • Exchange
  • TVTX Nasdaq
  • NAMS Nasdaq
  • Market Cap
  • TVTX 1.6B
  • NAMS 1.7B
  • IPO Year
  • TVTX N/A
  • NAMS N/A
  • Fundamental
  • Price
  • TVTX $17.37
  • NAMS $25.50
  • Analyst Decision
  • TVTX Buy
  • NAMS Strong Buy
  • Analyst Count
  • TVTX 13
  • NAMS 6
  • Target Price
  • TVTX $23.46
  • NAMS $36.20
  • AVG Volume (30 Days)
  • TVTX 1.4M
  • NAMS 1.4M
  • Earning Date
  • TVTX 02-13-2025
  • NAMS 02-06-2025
  • Dividend Yield
  • TVTX N/A
  • NAMS N/A
  • EPS Growth
  • TVTX N/A
  • NAMS N/A
  • EPS
  • TVTX N/A
  • NAMS N/A
  • Revenue
  • TVTX $203,447,000.00
  • NAMS $33,594,000.00
  • Revenue This Year
  • TVTX $62.17
  • NAMS $129.49
  • Revenue Next Year
  • TVTX $56.38
  • NAMS N/A
  • P/E Ratio
  • TVTX N/A
  • NAMS N/A
  • Revenue Growth
  • TVTX 57.08
  • NAMS 78.77
  • 52 Week Low
  • TVTX $5.12
  • NAMS $10.50
  • 52 Week High
  • TVTX $20.33
  • NAMS $27.29
  • Technical
  • Relative Strength Index (RSI)
  • TVTX 43.48
  • NAMS 62.30
  • Support Level
  • TVTX $16.66
  • NAMS $24.40
  • Resistance Level
  • TVTX $19.20
  • NAMS $26.95
  • Average True Range (ATR)
  • TVTX 0.74
  • NAMS 1.66
  • MACD
  • TVTX -0.24
  • NAMS 0.41
  • Stochastic Oscillator
  • TVTX 23.24
  • NAMS 81.51

Stock Price Comparison Chart: TVTX vs NAMS

TVTX
NAMS
AprilJulyOctober2022AprilJulyOctober2023AprilJulyOctober2024AprilJulyOctober05101520253035TVTX VS NAMS

About TVTX Travere Therapeutics Inc.

Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN) - rare kidney disorders that often cause end-stage kidney disease.

About NAMS NewAmsterdam Pharma Company N.V.

NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments.

Share on Social Networks:

0

By browsing this website, you accept our Privacy Policy & Terms of Use